Making a difference for traumatic brain injury patients
Emerging new Company veriNOS pharmaceuticals, established in October 2022, Led by CEO, Christian Wandersee and CMO Professor John Stover, provides an update on its revival of late-stage drug candidate ronopterin for the treatment of Traumatic Brain Injury (TBI). Ronopterin is the first and only iNOS inhibitor which has demonstrated repeated signs of neuroprotection in TBI […]